BioCapTM IFNLR1 (IL28RA) mRNA
Catalog Number: 1402001| SKU | Price | Buy |
|---|---|---|
| 1402001-500ug | $1,550.00 | |
| 1402001-1mg | $2,025.00 |
Description
IFNLR1 (IL28RA) / IL28RA LICR2
SPECIES:
Human
ENCODED PROTEIN NAME:
Interferon lambda receptor 1
Function:
The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state. Determines the cell type specificity of the lambda interferon action. Shows a more restricted pattern of expression in the epithelial tissues thereby limiting responses to lambda interferons primarily to epithelial cells of the respiratory, gastrointestinal, and reproductive tracts. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. (Source: UniProt http://www.uniprot.org/uniprot/q8iu57)
Sequence (520 aa):
For the DNA coding sequence that is used as the template to synthesize the IFNLR1 (IL28RA) mRNA mimetic, please contact us at customerservice@pharna.com.
For potential mRNA mimetics encoding splice variants or isoforms of your interest, please contact us at customerservice@pharna.com and it is our promise to fulfill your needs.
PhaRNA, LLC is looking for academic and industry collaborators and partners to co-develop RNA-based therapeutics including vaccines for the prevention or treatment of microbial diseases caused by parasites, fungi, viruses and bacteria. Our company’s proprietary technology has the versatility of rapidly designing RNA-based products for testing and development in preclinical and clinical settings. More specifically, we are looking for potential collaborators and partners who have the capacity to take our custom-designed RNA products and test their efficacy using molecular, cell biological and animal models. We will then partner to develop the most promising drug candidates through early phase clinical studies. We believe that this form of collaboration will capitalize on the strengths of PhaRNA, LLC and the partnering organization to rapidly test and develop potentially life-saving drugs and vaccines. Interested parties, please contact us directly.